UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Bioanalytical Systems, Inc.
-------------------------------------------------------------------------------
(Name of Issuer)
Common Shares
-------------------------------------------------------------------------------
(Title of Class of Securities)
09058M 10 3
-------------------------------------------------------------------------------
(CUSIP Number)
Peter T. Kissinger, Ph.D.
111 Lorene Place
West Lafayette, IN 47906-8620
Copy to:
James A. Aschleman
Baker & Daniels LLP
900 E. 96th Street, Suite 600
Indianapolis, IN 46240
-------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
June 5, 2009
-------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of Sections 240.13d-l(e),
240.13d-l(f) or 240.13d-1(g), check the following box. |X|
Note: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all exhibits.
See Section 240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a
prior cover page.
The information required on the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the
liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).
CUSIP No. 09058M 10 3
-------------------------------------------------------------------------------
1. Name of Reporting Person.
Peter T. Kissinger, Ph.D.
-------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) |X|
(b) |_|
-------------------------------------------------------------------------------
3. SEC Use Only
-------------------------------------------------------------------------------
4. Source of Funds (See Instructions): PF (see Item 3)
-------------------------------------------------------------------------------
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e) |_|
-------------------------------------------------------------------------------
6. Citizenship or Place of Organization: United States
-------------------------------------------------------------------------------
Number of 7. Sole Voting Power 427,747
Shares -----------------------------------------------------
Beneficially
Owned by Each 8. Shared Voting Power 848,220 (1)
Reporting -----------------------------------------------------
Person With
9. Sole Dispositive Power 427,747
-----------------------------------------------------
10. Shared Dispositive Power 848,220 (1)
-----------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person: 1,275,967 (1)
-------------------------------------------------------------------------------
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions) |_|
-------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11): 26.0% (1)(2)
-------------------------------------------------------------------------------
14. Type of Reporting Person (See Instructions) IN
-------------------------------------------------------------------------------
----------
(1) Dr. Kissinger shares voting and dispositive power over these shares with
his spouse. Includes 1,354 shares indirectly held by Ms. Kissinger as
custodian for the benefit of their children.
(2) Based on 4,915,318 of the Company's Common Shares which were outstanding
as of May 1, 2009.
CUSIP No. 09058M 10 3
-------------------------------------------------------------------------------
1. Name of Reporting Person.
Candice B. Kissinger
-------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) |X|
(b) |_|
-------------------------------------------------------------------------------
3. SEC Use Only
-------------------------------------------------------------------------------
4. Source of Funds (See Instructions): PF (see Item 3)
-------------------------------------------------------------------------------
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e) |_|
-------------------------------------------------------------------------------
6. Citizenship or Place of Organization: United States
-------------------------------------------------------------------------------
Number of 7. Sole Voting Power 252,310 (1)
Shares -----------------------------------------------------
Beneficially
Owned by Each 8. Shared Voting Power 1,023,657 (2)
Reporting -----------------------------------------------------
Person With
9. Sole Dispositive Power 252,310 (1)
-----------------------------------------------------
10. Shared Dispositive Power 1,023,657 (2)
-----------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person:
1,275,967 (1)(2)
-------------------------------------------------------------------------------
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions) |_|
-------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11): 26.0% (1)(2)(3)
-------------------------------------------------------------------------------
14. Type of Reporting Person (See Instructions) IN
-------------------------------------------------------------------------------
----------
(1) Includes 1,354 shares indirectly held by Ms. Kissinger as custodian for
the benefit of their children.
(2) Ms. Kissinger shares voting and dispositive power over these shares with
her spouse.
(3) Based on 4,915,318 of the Company's Common Shares which were outstanding
as of May 1, 2009.
Explanatory Note
This statement constitutes Amendment No. 1 to the Schedule 13D filed
by Peter T. Kissinger, Ph.D. and Candice B. Kissinger (collectively, the
"Kissingers") on April 6, 2009. Except as specifically set forth herein, the
Schedule 13D remains unmodified.
Item 4 is hereby amended to add the following:
Item 4. Purpose of Transaction
On June 5, 2009, the Kissingers provided a follow-up letter dated
June 5, 2009 (the "Letter") to the Board of Directors of Bioanalytical
Systems, Inc. (the "Issuer"). The Letter set forth the biographical information
for the three director candidates proposed by the Kissingers to replace three
of the current members of the Issuer's Board of Directors. The Letter also
indicated that, after reviewing the Schedule 13D/A filed by Thomas A. Harenburg
on May 14, 2009, the Kissingers support Jerome G. Marchant, the director
candidate proposed by Mr. Harenburg, replacing another current member of the
Issuer's Board of Directors. A copy of the Letter is filed herewith and
attached hereto as Exhibit 99.3 and incorporated herein by reference. Any
descriptions herein of the Letter are qualified in their entirety by reference
to the Letter.
Item 7 is hereby amended to add the following exhibit:
Item 7. Material to Be Filed as Exhibits
Exhibit 99.3 - Letter from Peter T. Kissinger, Ph.D. and
Candice B. Kissinger to the Board of Directors of Bioanalytical Systems,
Inc., dated June 5, 2009
-------------------------------------------------------------------------------
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete
and correct.
Dated: June 5, 2009
By: /s/ Peter T. Kissinger, Ph.D.
---------------------------------------
Peter T. Kissinger, Ph.D.
By: /s/ Candice B. Kissinger
---------------------------------------
Candice B. Kissinger